- Home
- DC vs FTRE Comparison
DC vs FTRE Comparison
Compare DC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DC | FTRE |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 843.8M | 829.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | DC | FTRE |
|---|---|---|
| Price | $5.79 | $13.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $9.48 | ★ $14.06 |
| AVG Volume (30 Days) | 994.1K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $2.85 | $3.97 |
| 52 Week High | $7.25 | $18.67 |
Technical Indicators
Market Signals| Indicator | DC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 59.26 |
| Support Level | $5.75 | $8.85 |
| Resistance Level | $5.90 | $18.26 |
| Average True Range (ATR) | 0.27 | 0.82 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 42.34 | 54.77 |
Price Performance
Historical ComparisonAbout DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company focused on revitalizing the Homestake District in Lead, South Dakota. The company holds gold mineral properties surrounding the historic Homestake Mine and is advancing key projects, including the Richmond Hill Project.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.